Effect of EGFRvⅢ expression on sensitivity of ovarian cancer SKOV3 cell after Gefitinib treatment

ZHANG Li; BAO Lewen

您当前的位置：

首页 >

文章列表页 >

Effect of EGFRvⅢ expression on sensitivity of ovarian cancer SKOV3 cell after Gefitinib treatment

更新时间：2023-12-18

- Effect of EGFRvⅢ expression on sensitivity of ovarian cancer SKOV3 cell after Gefitinib treatment
- Journal of Chongqing Medical University Vol. 37, Issue 11, Pages: 940-942(2012)
- 作者机构：
  
  1. 天津医科大学附属肿瘤医院妇瘤科,天津,300060
  2. 天津市肿瘤防治重点实验室,天津,300060
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2012，
扫描看全文
ZHANG Li, BAO Lewen. Effect of EGFRvⅢ expression on sensitivity of ovarian cancer SKOV3 cell after Gefitinib treatment. [J]. Journal of Chongqing Medical University 37(11):940-942(2012)
DOI：

ZHANG Li, BAO Lewen. Effect of EGFRvⅢ expression on sensitivity of ovarian cancer SKOV3 cell after Gefitinib treatment. [J]. Journal of Chongqing Medical University 37(11):940-942(2012) DOI：

摘要

目的：探讨EGFRvⅢ的表达与卵巢癌SKOV3细胞对化疗药吉非替尼敏感性之间的关系，为临床治疗并合理选用抗肿瘤药物提供参考。方法：将质粒pcDNA4/TO-EGFRvⅢ稳定转染入SKOV3细胞，并用zeocin抗生素筛选出稳定表达EGFRvⅢ蛋白的细胞株（命名为SKOV3-EGFRvⅢ），用MTT法检测转染稳定株和原始株在吉非替尼作用下细胞的存活能力。然后，以吉非替尼分别对2株细胞建立的裸鼠异体肿瘤模型进行治疗，通过测量肿瘤体积大小评价肿瘤模型对吉非替尼的敏感性。结果：通过Western blot 鉴定，SKOV3-EGFRvⅢ稳定株建立成功；MMT法结果表明SKOV3-EGFRvⅢ细胞在吉非替尼的作用下，其死亡率低于原始细胞株，且吉非替尼对SKOV3-EGFRvⅢ细胞建立的裸鼠肿瘤模型的抑制效果明显低于原始细胞株。结论：EGFRvⅢ的过表达导致卵巢癌SKOV3细胞及其体外移植肿瘤模型对化疗药吉非替尼的敏感性减弱。

Abstract

Objective：To determine the relationship between EGFRvⅢ expression and sensitivity of SKOV3 cell to Gefitinib and to give rational guidance to clinical medication. Methods：Plasmid pcDNA4/TO-EGFRvⅢ was stably transfected into SKOV3 cell and the cell strains stably expressing EGFRvⅢ were screened out by zeocin antibiotics and named SKOV3-EGFRvⅢ. MTT was used to assess the viability of SKOV3- EGFRvⅢ cell and SKOV3 cell treated by Gefitinib. Nude mice allograft tumor models bearing SKOV3 and SKOV-EGFRvⅢ were treated by Gefitinib. The sensitivity of the tumor model to Gefitinib was assessed by measuring the tumor size. Results：Results of Western blot indicated that SKOV3-EGFRvⅢ cell strain was successfully established. According to the results of MMT，after being treated by Gefitinib，the mortality was lower in SKOV3-EGFRvⅢ cell than in SKOV3 cell and the inhibi－tion effect of Gefitinib was less intense on tumor model carrying SKOV3-EGFRvⅢ cell than on that carrying SKOV3. Conclusion：Over expression of EGFRvⅢ in ovarian cancer SKOV3 cell results in its decreased sensitivity to Gefitinib.

关键词

EGFRvⅢSKOV3细胞敏感性吉非替尼

Keywords

EGFRvⅢSKOV3 cellsensitivitygefitinib

references

Views

865

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with docetaxel monotherapy in previously treated advanced non-small-cell lung cancer:a Meta-analysis

Effect of connexin 43 on the primary resistance to gefitinib in non-small-cell lung cancer cells

Research on the relation between expression GRP78 in gastric cancer cell lines and its sensitivity to chemotherapeutic drugs

Effects of phosphoinositide 3-kinase inhibitor on the proliferation and migration of triple-negative breast cancer cell lines

Clinical observation of gefitinib combined with Endostar in the first-line treatment of EGFR mutation positive advanced lung adenocarcinoma

Related Author

Jiang Youfan

Jiang Depeng

Yang Yingqing

Yang Jie

Qin Guihui

Huang Guolin

Teng Cuifang

Luo Min

Related Institution

Department of Respiratory Diseases,the Second Affiliated Hospital,Chongqing Medical University

Department of Pharmacology,School of Pharmacy,Guangxi Medical University

Department of Gastroenterology,the First Affiliated Hospital,Chongqing Medical University

Key Laboratory of Molecular Pharmacology，Chongqing Medical University

Center of Pharmacology and Toxicology，Chongqing Fochon Pharmaceutical CO.，LTD

⁰